Open AccessBlood Pressure Effects of Naproxcinod in Hypertensive Patients
Author(s) -
Townsend Raymond,
Bittar Neville,
Rosen Jeffrey,
Smith William,
Ramsay Andrea,
Chrysant Steven G.,
Weiss Robert,
Pivodic Aldina,
Duquesroix Brigitte,
Djian Jacques
Publication year - 2011
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2010.00419.x
Subject(s) - medicine , naproxen , blood pressure , ambulatory blood pressure , morning , placebo , crossover study , ambulatory , anesthesia , alternative medicine , pathology
The blood pressure (BP) effects of naproxcinod and naproxen were assessed in an 8‐week, double‐blind, crossover study in 131 hypertensive patients aged 50 to 74 years. Patients received naproxcinod 750 mg twice daily or naproxen 500 mg twice daily, then the alternate treatment, each for 14 days, with placebo run‐in/washout before each active treatment period and 24‐hour ambulatory BP monitoring conducted before and after each active treatment period. Mean change from baseline in average 24‐hour systolic BP (SBP) after 2 weeks of treatment numerically favored naproxcinod 750 mg twice daily (least‐squares [LS] mean for naproxcinod minus naproxen: −1.6 mm Hg; P=.12). Post hoc analyses showed statistically significant SBP differences favoring naproxcinod for the 8 elapsed hours (LS mean: −4.4 mm Hg; P<.0001) and the 24 hours following morning dosing (LS mean: −2.4 mm Hg; P=.006). Naproxcinod may be a beneficial alternative for patients with osteoarthritis requiring nonsteroidal anti‐inflammatory drugs. J Clin Hypertens (Greenwich) . 2011;13:376–384. ©2011 Wiley Periodicals, Inc.